As we learn more about GLP-1 drugs like Wegovy and Zepbound, early research suggests that they may be able to improve COPD ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

GLP-1RA use, but not SGLT2i or pioglitazone use, was associated with a statistically significant lower risk for dementia and cognitive impairment.